Dirk Schadendorf

221.9k total citations · 15 hit papers
982 papers, 46.5k citations indexed

About

Dirk Schadendorf is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Dirk Schadendorf has authored 982 papers receiving a total of 46.5k indexed citations (citations by other indexed papers that have themselves been cited), including 621 papers in Oncology, 498 papers in Molecular Biology and 295 papers in Immunology. Recurrent topics in Dirk Schadendorf's work include Melanoma and MAPK Pathways (305 papers), Cutaneous Melanoma Detection and Management (248 papers) and Immunotherapy and Immune Responses (244 papers). Dirk Schadendorf is often cited by papers focused on Melanoma and MAPK Pathways (305 papers), Cutaneous Melanoma Detection and Management (248 papers) and Immunotherapy and Immune Responses (244 papers). Dirk Schadendorf collaborates with scholars based in Germany, United States and France. Dirk Schadendorf's co-authors include Reinhard Dummer, Caroline Robert, Axel Hauschild, Antje Sucker, Selma Ugurel, Claus Garbe, Jedd D. Wolchok, F. Stephen Hodi, Yuansheng Sun and Selma Alijagic and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Dirk Schadendorf

942 papers receiving 45.7k citations

Hit Papers

Vaccination of melanoma p... 1998 2026 2007 2016 1998 2015 2013 2012 2018 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
    1998 2.4k citations Reinhard Dummer, Dirk Schadendorf et al. profile →
  2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
    2015 1.6k citations Dirk Schadendorf, Caroline Robert et al. Journal of Clinical Oncology profile →
  3. TERT Promoter Mutations in Familial and Sporadic Melanoma
    2013 1.3k citations Susanne Horn, Adina Figl et al. Science profile →
  4. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
    2012 1.1k citations Keith T. Flaherty, Caroline Robert et al. profile →
  5. Melanoma
    2018 1.0k citations Dirk Schadendorf, Klaus Griewank et al. profile →
  6. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
    2018 1.0k citations Dirk Schadendorf, Reinhard Dummer et al. profile →
  7. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
    2000 936 citations Jean‐Jacques Grob, Dirk Schadendorf et al. Journal of Clinical Oncology profile →
  8. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    2009 934 citations Dirk Schadendorf, Jean‐Jacques Grob et al. profile →
  9. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
    2017 874 citations Dirk Schadendorf, Georgina V. Long et al. Journal of Clinical Oncology profile →
  10. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
    2018 675 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
  11. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    2013 499 citations Paolo A. Ascierto, Dirk Schadendorf et al. profile →
  12. Melanoma
    2015 441 citations Dirk Schadendorf, Claus Garbe et al. profile →
  13. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
    2018 392 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
  14. Metabolic heterogeneity confers differences in melanoma metastatic potential
    2019 355 citations Dirk Schadendorf et al. profile →
  15. Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review
    2018 296 citations Jochen Utikal, Dirk Schadendorf et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Dirk Schadendorf 27.6k 21.3k 15.5k 4.5k 4.2k 982 46.5k
John M. Kirkwood 31.3k 1.1× 17.9k 0.8× 18.8k 1.2× 4.4k 1.0× 3.9k 0.9× 687 46.4k
Keith T. Flaherty 24.8k 0.9× 23.3k 1.1× 7.1k 0.5× 6.3k 1.4× 5.7k 1.3× 518 39.7k
Richard A. Scolyer 21.3k 0.8× 13.3k 0.6× 6.6k 0.4× 3.8k 0.8× 4.3k 1.0× 707 30.6k
Michael B. Atkins 25.3k 0.9× 16.0k 0.7× 12.0k 0.8× 12.6k 2.8× 6.3k 1.5× 577 40.7k
Reinhard Dummer 22.4k 0.8× 19.1k 0.9× 14.7k 0.9× 3.4k 0.8× 2.8k 0.7× 951 44.0k
Georg Schett 8.7k 0.3× 21.6k 1.0× 18.0k 1.2× 4.8k 1.1× 4.3k 1.0× 1.1k 59.6k
Claus Garbe 21.3k 0.8× 15.0k 0.7× 7.0k 0.5× 2.6k 0.6× 2.2k 0.5× 750 34.4k
Donald L. Morton 22.7k 0.8× 10.4k 0.5× 8.8k 0.6× 3.7k 0.8× 4.0k 0.9× 448 33.4k
Antoni Ribas 39.7k 1.4× 27.4k 1.3× 22.6k 1.5× 7.5k 1.7× 6.3k 1.5× 551 61.0k
Michael T. Lotze 17.2k 0.6× 20.4k 1.0× 26.0k 1.7× 7.7k 1.7× 6.6k 1.6× 504 57.5k

Countries citing papers authored by Dirk Schadendorf

Since Specialization
Citations

This map shows the geographic impact of Dirk Schadendorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Schadendorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Schadendorf more than expected).

Fields of papers citing papers by Dirk Schadendorf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Schadendorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Schadendorf. The network helps show where Dirk Schadendorf may publish in the future.

Co-authorship network of co-authors of Dirk Schadendorf

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Schadendorf. A scholar is included among the top collaborators of Dirk Schadendorf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Schadendorf. Dirk Schadendorf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zaremba, Anne, Antje Sucker, Gennadiy Zelinskyy, et al.. (2023). HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance. Clinical Cancer Research. 29(15). 2894–2907. 9 indexed citations
2.
Ramsay, LeeAnn, et al.. (2021). Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. Clinical Cancer Research. 27(12). 3432–3442. 63 indexed citations
3.
Bezrookove, Vladimir, Mehdi Nosrati, James R. Miller, et al.. (2018). Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clinical Cancer Research. 24(17). 4119–4125. 10 indexed citations
4.
Young, Arabella, Shin Foong Ngiow, Jason Madore, et al.. (2017). Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer Research. 77(17). 4684–4696. 76 indexed citations
5.
Ullrich, Nico, Anja Heinemann, Inka Scheffrahn, et al.. (2015). CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. Cancer Research. 75(9). 1897–1907. 23 indexed citations
6.
Gebhardt, Christoffer, Alexandra Sevko, Huanhuan Jiang, et al.. (2015). Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clinical Cancer Research. 21(24). 5453–5459. 290 indexed citations
7.
Santiago-Walker, Ademi, Robert Gagnon, Jolly Mazumdar, et al.. (2015). Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research. 22(3). 567–574. 158 indexed citations
8.
Zelba, Henning, Benjamin Weide, Alexander Martens, et al.. (2014). Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research. 20(16). 4390–4399. 35 indexed citations
9.
Sucker, Antje, Fang Zhao, Birgit Real, et al.. (2014). Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression. Clinical Cancer Research. 20(24). 6593–6604. 127 indexed citations
10.
Horn, Susanne, Adina Figl, P. Sivaramakrishna Rachakonda, et al.. (2013). TERT Promoter Mutations in Familial and Sporadic Melanoma. Science. 339(6122). 959–961. 1267 indexed citations breakdown →
11.
Ugurel, Selma, Thomas Mentzel, Jochen Utikal, et al.. (2013). Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up. Clinical Cancer Research. 20(2). 499–510. 100 indexed citations
12.
Weide, Benjamin, Alexander Martens, Henning Zelba, et al.. (2013). Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells. Clinical Cancer Research. 20(6). 1601–1609. 210 indexed citations
13.
Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations
14.
Zimmer, Lisa, Uwe Hillen, Elisabeth Livingstone, et al.. (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology. 30(19). 2375–2383. 167 indexed citations
15.
Eggermont, Alexander M.M., Stefan Suciu, Alessandro Testori, et al.. (2012). Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. Journal of Clinical Oncology. 30(31). 3810–3818. 190 indexed citations
16.
Nasarre, Patrick, Markus Thomas, Karoline Kruse, et al.. (2009). Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth. Cancer Research. 69(4). 1324–1333. 140 indexed citations
17.
Helfrich, Iris, Lutz Edler, Antje Sucker, et al.. (2009). Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma. Clinical Cancer Research. 15(4). 1384–1392. 152 indexed citations
18.
Bazhin, Alexandr V., Dirk Schadendorf, Robert W. Owen, et al.. (2008). Visible Light Modulates the Expression of Cancer-Retina Antigens. Molecular Cancer Research. 6(1). 110–118. 13 indexed citations
19.
Młynarczuk-Biały, Izabela, Ulrike Kuckelkorn, Boris Schmidt, et al.. (2006). Combined Effect of Proteasome and Calpain Inhibition on Cisplatin-Resistant Human Melanoma Cells. Cancer Research. 66(15). 7598–7605. 41 indexed citations
20.
Röhn, Till A., Annette Paschen, Xuan Duc Nguyen, et al.. (2005). A Novel Strategy for the Discovery of MHC Class II–Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope. Cancer Research. 65(21). 10068–10078. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John M. Kirkwood Breakdown of academic impact, for papers by Keith T. Flaherty Breakdown of academic impact, for papers by Richard A. Scolyer Breakdown of academic impact, for papers by Michael B. Atkins Breakdown of academic impact, for papers by Reinhard Dummer Breakdown of academic impact, for papers by Georg Schett Breakdown of academic impact, for papers by Claus Garbe Breakdown of academic impact, for papers by Donald L. Morton Breakdown of academic impact, for papers by Antoni Ribas Breakdown of academic impact, for papers by Michael T. Lotze
Rankless by CCL
2026